Abstract
Summary
1. Four hundred mg of Butazolidin were administered orally for 10 days to 11 normal students and to 6 patients with rheumatoid spondylitis. Plasma concentrations and total 24-hour urinary excretion values for the drug were estimated. 2. Butazolidin was demonstrated in the plasma of all individuals between the 1st and 3d days on treatment and appeared in the urine between the 1st and 5 th days thus proving its definite absorption in all 17 subjects. With the exception of 2 mild cases of edema in 2 females in the normal group, no toxic effects of the drug were encountered during therapy. There were no significant differences in the reactions in the 2 groups. No sex differences were noted in the rate of absorption or excretion of the drug although the number of subjects admittedly was small. 3. Butazolidin did not completely disappear from the urine in one patient with osteo arthritis until 12 days following cessation of therapy and it was still detected in small amounts in the plasma at the end of 15 days. 4. We have at this time no adequate explanation regarding the disposition of the drug by the body although there is some evidence to suggest that a part of it is stored as Butazolidin in the tissues or carried in the circulating blood.
Get full access to this article
View all access options for this article.